Clinical data | |||
---|---|---|---|
Other names | HNK; 6-Hydroxynorketamine; 6-HNK | ||
ATC code |
| ||
Identifiers | |||
| |||
CAS Number | |||
PubChem CID | |||
ChemSpider | |||
UNII | |||
CompTox Dashboard (EPA) | |||
Chemical and physical data | |||
Formula | C12H14ClNO2 | ||
Molar mass | 239.70 g·mol−1 | ||
3D model (JSmol) | |||
| |||
|
Hydroxynorketamine (HNK), or 6-hydroxynorketamine, is a minor metabolite of the anesthetic, dissociative, and antidepressant drug ketamine.[1] It is formed by hydroxylation of the intermediate norketamine, another metabolite of ketamine.[1] As of late 2019, (2R,6R)-HNK is in clinical trials for the treatment of depression.[2]
The major metabolite of ketamine is norketamine (80%).[3] Norketamine is secondarily converted into 4-, 5-, and 6-hydroxynorketamines (15%), mainly HNK (6-hydroxynorketamine).[3] Ketamine is also transformed into hydroxyketamine (5%).[3] As such, bioactivated HNK comprises less than 15% of a dose of ketamine.[3]
Hashimoto2019
was invoked but never defined (see the help page).